Therapy-induced antibodies against the antiviral and antiproliferative effects of interferons in patients with chronic hepatitis C virus infection

Acta Microbiologica et Immunologica Hungarica

Volumn 51, Issue 3, 2004, Pages 359-369

  Bálint, Erzsébet ^a   Bakay, Márta ^b   Ónody, Klára ^c   Farkas, F ^c   Horvath G ^d   Tolvaj, G Y ^d   David K ^d   Horányi, Margit ^e   Béládi, Ilona ^b  

^a Dept of Opt and Quant Electronics ^*  (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c EGIS PHARMACEUTICALS LTD   (Hungary)

^d Centr Hosp of Min of the Interior   (Hungary)

^e NATIONAL MEDICAL CENTER   (Hungary)

Author keywords

Anti interferon antibodies; Antiviral and antiproliferative effects of interferon; Chronic hepatitis C virus infection; Natural and recombinant interferons

Indexed keywords

ALPHA INTERFERON; CYTOKINE ANTIBODY; EGIFERON; INTERFERON BINDING ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DAUDI CELL; DRUG ACTIVITY; DRUG EFFECT; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 8844250085     PISSN: 12178950     EISSN: None     Source Type: Journal    
DOI: 10.1556/AMicr.51.2004.3.13     Document Type: Article

References (22)

1. Di Bisceglie, A. M., Hoofnagle, J. H.: Optimal therapy of hepatitis C. Hepatology 36, S121 (2002).
2. Vallbracht, A., Treuner, T., Flehmig, B., Joester, K. E., Niethammer, D.: Interferon neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 289, 496 (1981).
3. Steis, R. G., Smith, J. W., Urba, W. J., Clark, J. W., Itri, L. M., Evans, L. M., Schoenberger, C., Longo, D. L.: Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 318, 1409 (1988).
4. Bekisz, J. B., Zur Nedden, D. L., Enterline, J. C.: Antibodies to interferon-alpha-2 in patients treated with interferon-alpha-2 for hairy cell leukemia. J Interferon Res 9, Suppl. 1, S1 (1989).
5. Antonelli, G., Currenti, M., Turriziani, O., Dianzani, F.: Neutralizing antibodies to interferon-α relative frequency in patients treated with different interferon preparations. J Infect Dis 163, 882 (1991).
6. Rönnblom, L. E., Tiensuu Janson, E., Perers, A., Öberg, K. E., Alm, G. V.: Characterization of anti-interferon-α antibodies appearing during recombinant interferon-α2a treatment. Clin Exp Immunol 89, 330 (1992).
7. Brand, C. M., Leadbeater, L.: Specificities of therapy-induced anti-interferon-α antibodies. J Interferon Res 14, 201 (1994).
8. Prümmer, O., Bunjes, D., Wiesneth, M., Arnold, R., Porzsolt, F., Heimpel, H.: High-titre interferon-α antibodies in patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 14, 483 (1994).
9. Weck, P. K., Leventhal, B. G., Brand, C., Finter, N. B.: Detection and incidence of neutralizing antibodies to interferon-α-n1. J Interferon Res 9, Suppl. 1, S37 (1989).
10. Tanaka, H., Tsukuma, H., Kasahara, A., Hayashi, N., Yoshihara, H., Masuzawa, M., Kanda, T., Kashiwagi, T., Inoue, A., Kato, M., Oshima, A., Kinoshita, Y., Kamada, T.: Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 87, 741 (2000).
11. Toyoda, H., Kumada, T., Nakano, S., Takeda, I., Sugiyama, K., Seiki, K., Sone, Y., Hisanaga, Y.: The effect of retreatment with interferon-α on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Cancer 88, 58 (2000).
12. Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., Albrecht, J.: Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepstitis C virus. Lancet 352, 1426 (1998).
13. Fried, M. W.: Side effects of therapy of hepatitis C and their management. Hepatology 36, Suppl. 1, S237 (2002).
14. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Jr., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., Yu, J.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347, 975 (2002).
15. Antonelli, G., Gianelli, G., Pistello, M., Maggi, F., Vatteroni, L., Currenti, M., Del Vecchio, S., Roffi, L., Pastore, G., Dianzani, F.: Clinical significance of recombinant interferon-α2 neutralizing antibodies in hepatitis patients. J Interferon Res 14, 211 (1994).
16. Roffi, L., Mels, G. C., Antonelli, G., Bellati, G., Panizzuti, F., Piperno, A., Pozzi, M., Ravizza, D., Angeli, G., Dianzani, F., Mancia, G.: Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology 21, 645 (1995).
17. Leroy, V., Baud, M., de Traversay, C., Maynard-Muet, M., Lebon, P., Zarski, J-P.: Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. J Hepatol 28, 375 (1998).
18. Stancek, D., Fuchsberger, N., Oltman, M., Schmeisser, H., Kontsek, P., Jahnová, E., Hajnická, V.: Significance of anti-interferon- α2 and sICAM-1 activities in the sera of viral hepatitis B and C patients treated with human recombinant interferon-α2. Acta Virol 45, 287 (2001).
19. Gianelli, G., Antonelli, G., Fera, G., Del Vecchio, S., Riva, E., Broccia, C., Schiraldi, O., Dianzani, F.: Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-α) during therapy of chronic hepatitis C. Clin Exp Immunol 97, 4 (1994).
20. Bonino, F., Baldi, M., Negro, F., Oliveri, F., Colombatto, P., Bellati, G., Brunetto, M. R.: Clinical relevance of anti-interferon antibodies in the serum of chronic hepatitis C patients treated with interferon-α. J Interferon Cytokine Res 17, Suppl. 1, S35 (1997).
21. Hou, C., Chuang, W-L., Yu, M-L., Dai, C-Y., Chen, S-C., Lin, Z-Y., Hsieh, M-Y., Wang, L-Y., Tsai, J-F., Chang, W-Y.: Incidence and associated factors of neutralizing anti-interferon antibodies among chronic hepatitis C patients treated with interferon in Taiwan. Scand J Gastroenterol 35, 1288 (2000).
22. Kishihara, Y., Ikematsu, H., Hayashi, J., Jamaji, K., Kashiwagi, S.: Serum antibody to natural interferon-alpha of the IgG class among hepatitis C virus carriers and their relevance to interferon therapy on chronic hepatitis. IX. Triennial International Symposium on Viral Hepatitis and Liver Disease, Rome. D161, 320 (1996).